10-Q: NovelStem International Corp. Reports Q1 2025 Results, Focuses on Liquidity and Asset Monetization

NovelStem International Corp. reports a net loss for Q1 2025 and is focused on securing additional funding and monetizing assets to address going concern uncertainties.

Summary

• NovelStem International Corp. reported a net loss of $207,216 for the three months ended March 31, 2025, compared to a net loss of $303,280 for the same period in 2024.
• The company's current assets were $21,747, and current liabilities were $5,492,837 as of March 31, 2025.
• Management is focused on additional financing, fundraising, and monetization of assets, including the sale of NetCo to its joint venture partner.
• The company's ability to continue as a going concern is dependent on obtaining additional funding and monetizing assets.
• A settlement agreement was reached on May 9, 2025, to monetize the NetCo investment and settle the litigation funding liability to OmniBridgeway in full for $1,300,000.
• The company has identified a material weakness in its internal control over financial reporting related to insufficient resources for proper segregation of duties.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's significant losses, liquidity issues, going concern uncertainties, and material weakness in internal controls. While there are some positive developments, such as the decrease in net loss and the monetization of NetCo, the overall financial situation remains precarious.

Positives

• The net loss decreased from $303,280 in Q1 2024 to $207,216 in Q1 2025.
• The company successfully monetized its investment in NetCo to settle a significant liability.
• The company is actively pursuing additional financing and fundraising opportunities.

Negatives

• The company has a significant accumulated deficit of approximately $297,000,000.
• Current liabilities significantly exceed current assets, indicating a liquidity crisis.
• The investment in NewStem has been fully impaired due to its liquidation status.
• There is substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting has been identified.

Risks

• The company's ability to obtain additional funding is uncertain.
• The monetization of NewStem's intangible assets is uncertain.
• The company's high level of debt and accrued interest poses a significant financial burden.
• The material weakness in internal control over financial reporting could lead to material misstatements in financial statements.

Future Outlook

The company's future is dependent on obtaining additional funding, monetizing assets, and the potential profitability of NewStem's technology.

Management Comments

• Management's plans include additional financing and fundraising as well as monetization of assets held related to equity method investments.
• Specifically, the Company is in the final stages of the process of selling NetCo to its joint venture partner in a transaction that satisfies the related debt (litigation funding agreement).

Industry Context

The company operates in the biotech and media industries, both of which are highly competitive and subject to rapid change. The company's success depends on its ability to innovate and adapt to changing market conditions.

Comparison to Industry Standards

• Given NovelStem's stage and financial position, direct comparisons to industry giants are not meaningful.
• However, the company's focus on asset monetization and strategic partnerships aligns with common practices among smaller companies in the biotech and media sectors seeking to maximize shareholder value.
• For example, many small biotech firms like NovalStem seek funding from litigation funding firms such as Omni Bridgeway.
• The company's reliance on related-party debt is a common practice among small companies with limited access to traditional financing.

Legal Proceedings

• The company was the claimant in an arbitration proceeding against their 50 % partner in NetCo.
• The Arbitrator ruled in NovelStems favor on the issue of contract interpretation of the Netco Partners JV Agreement.
• The Arbitrator also found that the Companys joint venture partner failed to use reasonable, good faith efforts to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners Joint Venture Agreement.
• The Arbitrator confirmed NovelStems contractual right to use Tom Clancys name as a possessory credit in the Net Force title (Tom Clancys Net Force).

Related Party Transactions

• The company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a shareholder and member of the Board, to borrow up to an aggregate of $600,000 for working capital needs.
• During the three months ended March 31, 2025, Jan Loeb, Executive Chairman, began advancing funds to the Company for operating expenses in the form of an interim bridge loan until alternate funding sources can be found.
• On May 5, 2023, the Company entered into a long-term note payable with a shareholder for $300,000 in financing.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainties.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Creditors face increased risk of non-payment due to the company's liquidity issues.

Next Steps

• The company needs to secure additional funding to continue operations.
• Management plans to monetize assets held related to equity method investments.
• The company needs to address the material weakness in its internal control over financial reporting.

Key Dates

Keywords

NovelStem, NetCo, NewStem, Liquidation, Litigation Funding, Going Concern, Convertible Debt, Financial Statements, Q1 2025, Impairment